What happened

At its 2026 interim results conference on August 31, PICC reported insurance service revenue of 286.873 billion yuan, up 2.4% year on year, and attributable net profit of 36.745 billion yuan, up 38.5%. The company proposed an interim cash dividend of 0.11 yuan per share, with total payout of 4.865 billion yuan, up 46.7% from the 2025 interim dividend.

President Zhao Peng said PICC is not considering alternative profit measures such as operating profit as its dividend basis, citing differences in business structure from listed peers. Under new accounting rules that amplify the impact of short-term market swings on earnings, he said the company relies on a 'dual-wheel drive' of underwriting and investment to maintain stable long-term profitability.

In property and casualty insurance, underwriting profit rose 19.8% to 14.010 billion yuan and the comprehensive cost ratio improved to 94.5%. Auto insurance service revenue grew 1.9% to 153.168 billion yuan, with a cost ratio of 93.5%. Vice President Zhang Daoming linked lower claim frequency to an aging vehicle fleet and deeper use of smart driving technology. On investment, total investment income reached 66.327 billion yuan, up 59.9%, while the company net bought about 30 billion yuan in A-shares and built a strategic TPL equity portfolio that returned 21.1%, beating the CSI A500 by 7.2 percentage points. Vice President Cai Zhiwei highlighted PICC's early stake in Changxin Technology, whose valuation has grown more than 20-fold since the initial investment, and outlined a 'two-way empowerment' model focusing on AI, green energy, advanced manufacturing and other strategic sectors.

Why it matters

PICC's dividend stance is notable because new accounting standards make reported earnings more sensitive to capital market fluctuations. By sticking with reported profit as the dividend base, the company signals confidence in its ability to manage short-term volatility through underwriting and investment coordination, while the sharp increase in the interim payout underscores cash generation strength.

The underwriting trends point to structural shifts in China's auto insurance market: an older vehicle mix and smart driving technology are reducing claim frequency even as average claim costs rise, while regulatory measures against non-auto insurance disorderly competition are expected to keep expense ratios in check. These factors could support industry-wide profitability, not just for PICC.

PICC's expanding equity allocation and focus on technology and strategic sectors reflect the broader push for long-term capital in China's markets. Its involvement in Changxin Technology shows how insurers can pair insurance protection with patient capital to support innovation and potentially earn outsized returns, a model the company plans to extend to other priority areas.

Key facts

PICC's 2026 H1 insurance service revenue rose 2.4% year on year to 286.873 billion yuan.

Group net profit attributable to the parent grew 38.5% to 36.745 billion yuan in H1 2026.

PICC proposed an interim cash dividend of 0.11 yuan per share, totalling 4.865 billion yuan, up 46.7% from 2025 interim.

PICC P&C underwriting profit rose 19.8% to 14.010 billion yuan, with a comprehensive cost ratio of 94.5%.

Auto insurance comprehensive cost ratio fell 0.7 percentage points to 93.5%, and underwriting profit rose 13.6% to 9.917 billion yuan.

PICC net bought about 30 billion yuan of A-shares in H1 2026; its strategic TPL equity portfolio gained 21.1%, outperforming the CSI A500 by 7.2 percentage points.

What to watch next

Whether PICC's full-year auto comprehensive cost ratio indeed turns out better than the initial expectation of being roughly flat with 2025, and how smart driving adoption continues to reshape claim trends.

How the non-auto insurance comprehensive governance plan and China's anti-involution push affect PICC's expense ratios and market order in coming quarters.

How PICC's 'two-way empowerment' investment model develops across AI, green energy, advanced manufacturing, aerospace, biomedicine and other national strategic areas, and whether long-term equity bets such as Changxin Technology continue to deliver.

Sources